Arbutus Biopharma Corporation Q2 FY2024 earnings call

Arbutus Biopharma's focus is on developing hepatitis B therapeutics. Key programs include imdusiran and AB - 10l However, there is no detailed breakdown of financial performance by product segments in terms of absolute revenue and contribution % as the transcript does not present such segment - specific financial data.

• Prioritize advancing imdusiran to Phase 2b clinical development. • Expect preliminary data from nivolumab arm of improved two trial in H2 ️️️2024. • Cash runway extended into Q️4 2026 to fund anticipated imdusiran Phase 2b clinical trial.

Q:Dennis Ding asked about Phase 2b trial size, design, cost and inclusion of compounds.

A:Karen Sims stated it's premature to describe Phase 2b study design specifics and that they're evaluating all options for compounds in the trial. Q Roy Buchanan asked about next trial and focus on patients with baseline HBs less than ️️1,️️️000.

A:Michael McElhaugh discussed focusing on patients with baseline HBs less than a certain level and the large patient population, and said they're working on how to segment the market but there are substantial numbers of patients to work from. Q Keay Nakae asked about path forward for next clinical trial.

A:Michael McElhaugh said they're working to start the Phase 2b trial as quickly as possible, still waiting for data to drive the decision, and they have the legs to kick it off on their own with current cash on hand.